FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  ZELDIS JEROME B
2. Date of Event Requiring Statement (Month/Day/Year)
07/20/2015
3. Issuer Name and Ticker or Trading Symbol
BioSig Technologies, Inc. [BSGM]
(Last)
(First)
(Middle)
C/O BIOSIG TECHNOLOGIES, INC., 8441 WAYZATA BLVD., SUITE 240
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

MINNEAPOLIS, MN 55426
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.001 par value per share 137,245
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to Purchase Common Stock 04/09/2015 04/09/2025 Common Stock 300,000 $ 3.99 D  
Options to Purchase Common Stock   (1) 06/22/2025 Common Stock 50,000 $ 2.53 D  
Series C Preferred Stock   (2)   (2) Common Stock 42,334 $ 1.5 (2) D  
Warrants to Purchase Common Stock   (3) 01/09/2018 Common Stock 41,628 $ 1.5 D  
Warrants to Purchase Common Stock   (3) 07/15/2018 Common Stock 10,409 $ 1.5 D  
Warrants to Purchase Common Stock   (3) 10/14/2018 Common Stock 10,409 $ 1.5 D  
Warrants to Purchase Common Stock   (3) 01/31/2019 Common Stock 6,123 $ 3.67 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ZELDIS JEROME B
C/O BIOSIG TECHNOLOGIES, INC.
8441 WAYZATA BLVD., SUITE 240
MINNEAPOLIS, MN 55426
  X      

Signatures

/s/ Kenneth L. Londoner, attorney-in-fact 07/20/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The options vest in 12 consecutive monthly installments beginning one month from June 22, 2015, the date of the grant. As of the date of this report, the options are vested and exercisable as to zero underlying shares.
(2) The Series C Preferred Stock may be converted at any time at the option of the holder into shares of common stock at a conversion price of $1.50 per share. The Series C Preferred Stock has no expiration date.
(3) All Warrants are presently exercisable.
 
Remarks:
Exhibit 24.1 Power of Attorney (furnished herewith)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.